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The benefits of cardiac resynchronisation therapy (CRT) in
selected cohorts with systolic dysfunction and congestive
heart failure are well established [1–3]. CRT reduces heart
failure hospitalisations, decreases mortality, and improves the
quality of life and cardiac function, described as left ventric-
ular (LV) reverse remodelling. CRT improves inter-, intra- and
atrio-ventricular dyssynchrony. It is important to stress that
there is only a moderate correlation between clinical and
echocardiographic response; i.e. patients with improvement
in their clinical status might not always show significant
reverse remodelling. Nevertheless, the number of patients
who do not respond to this therapy remain as high as 30 %
to 40 %. The reasons for not responding to CRT are probably
complex and multifactorial. Patient selection, accurate assess-
ment of dyssynchrony, LV lead placement and optimal posi-
tion and device programming are of importance. This neces-
sitates a comprehensive evaluation of baseline and post-
implant clinical, electrocardiographic and echocardiographic
data. Moreover, LV lead position optimisation and device
interrogation are useful for optimising CRT and should be
considered to maximise the therapeutic response to CRT. It
is recommended to perform AV-delay optimisation in all
patients, guided either by the device or by echocardiography.
However, the role of AVand VVoptimisation regarding long-
term outcome remain debatable. The SMART AV trial [4]
showed that patients with normal AV delay did not derive
benefit from echo-guided or device-guided AV optimisation
compared with the empiric settings. However, patients with
prolonged AV conduction were not included in this prospec-
tive, randomised trial. Moreover, in the Freedom trial [5] the
authors concluded that routine AV and VV optimisation, by
echo or the QuickOpt algorithm in unselected CRT recipients,
did not appear to contribute significantly to further im-
proving responsiveness to CRT. A variety of techniques,
including echocardiography-guided methods, have been
described to determine the optimal AVand VV delays. Many
of these techniques have poor reproducibility and are time-
consuming [6, 7]. None of these techniques have been shown
to be superior and long-term benefits are lacking. Most
device-based algorithms allow a rapid, simplified approach
to CRT optimisation. However, their clinical value has also
been called into question. Only the CLEAR study [8, 9] results
suggest the clinical value of frequent CRT optimisation by
SonRTM algorithm or echocardiography in severe chronic
heart failure patients in the long-term.
Recently a new non-invasive finger plethysmographic
(Nexfin) method has been used for AV optimisation [10].
The Nexfin device, which allows measurement of beat-to-
beat stroke volume (SV), was validated against echocardiog-
raphy and the Riva-Rocci/Korotkoff method [11, 12] and AV
optimisation by this device led to an almost 7 % increase in
SV [10].
In this issue of the Journal, Molenaar et al.[13] present their
data on optimisation of CRT in clinical practice during exer-
cise using the Nexfin device. They found a heterogeneous
optimal AV delay in their small-sized study population. Cur-
rently, optimisation of pacing settings is mainly performed
during resting conditions [14].
A few questions can be asked. The first question is whether
the optimal AV delay changes during exercise in heart failure
patients? Bogaard et al. [14] reviewed the literature and found
seven small-sized studies which addressed this issue. The
reported results were not consistent: a shortening, lengthening
or no change in optimal AV delay during exercise was ob-
served. Based on the physiological properties of the AV node
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in healthy subjects, these heterogeneous responses to exercise
were unexpected [14]. The optimal physiological response to
exercise in heart failure patients is probably different compared
with healthy subjects. Thus, the findings of Molenaar et al. on
the true heterogeneous effect of AVoptimisation in heart failure
patients are in line with previous reports [14].
The second question is whether the programming of a rate-
adaptive AV delay has a significant influence on outcome. In
the same review by Bogaard et al. [14] it was concluded that in
all the studies only acute haemodynamic outcomes were
assessed. Molenaar et al. showed an increase of 10% in stroke
volume. This is again an acute haemodynamic measurement.
An interesting and relevant question is whether this adaptive
AV delay, which is a time-consuming method, has an influ-
ence on functional NYHA class and exercise capacity in heart
failure patients. Therefore, the long-term follow-up results of
their study will be very interesting.
Finally, Molenaar et al. used a non-invasive method pro-
vided by the Nexfin device, which is relatively new and is not
yet well validated for this purpose. Other methods such as
echocardiography, including transmitral flow and LV outflow
tract velocity (LVOT-VTI) measurements, have been used
much more in clinical practice [6, 7]. Nevertheless, these
methods are time-consuming and are moderately reproducible.
Device-based algorithms such as QuickOpt and Smart AV did
not show any benefit comparedwith nominal settings andwere
not tested during exercise. At the moment, programming a
sensed AV delay of 100–120 ms still seems the best practice
in the majority of patients until more data on clinical outcome
become available [4, 10, 14]. Currently, two multicentre and
randomised trials (Bio-Detect HF and Respond CRT) are
investigating the benefits of optimising AV and VV delay on
clinical outcome by device-based automated algorithm.
In summary, the 10 % increase in stroke volume due to AV-
delay optimisation by the Nexfin device during exercise, which
Molenaar et al. have showed, is a very interesting and encour-
aging result. However, the current methods of optimising rate-
adaptive AV delay, including the Nexfin method, need to be
tested in a larger number of patients with a longer follow-up
before definite conclusions can be made.
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